Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma

A Multicenter Clinical Study of Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma

This study aims to investigate the efficacy and safety of CD19/BCMA CAR-T cells in treating relapsed/refractory multiple myeloma.

Study Overview

• Status: Recruiting
• Conditions: Relapse Multiple Myeloma
• Intervention / Treatment: Other: Dual CD19/BCMA CAR-T

Detailed Description

B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T-cell (CAR-T) therapy is currently a crucial treatment for relapsed/refractory multiple myeloma, yet approximately half of patients still experience relapse with limited subsequent treatment options. Recent studies suggest that dual-target CAR-T may offer new hope for relapsed/refractory multiple myeloma. Preliminary studies in this project demonstrate that the independently designed CD19/BCMA CAR-T exhibits potent anti-myeloma activity both in vitro and in tumor-bearing animal models, positioning it as a potential therapeutic strategy for relapsed/refractory multiple myeloma. Therefore, this study aims to investigate the efficacy and safety of CD19/BCMA CAR-T cells in treating relapsed/refractory multiple myeloma in humans, with the goal of providing novel therapeutic approaches for this disease.

• Study Type: Interventional
• Enrollment (Estimated): 25
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Xuzhao Zhang; Phone Number: +86-571-89713679; Email: zxzzju@zju.edu.cn

Study Locations

• China
  • Hangzhou, China, 310003
    • Recruiting
    • Xuzhao Zhang
    • Contact: Xuzhao Zhang, Dr.; Phone Number: +086-571-89713679; Email: zxzzju@zju.edu.cn
    • Contact: Wenbin Qian, Dr.; Phone Number: +086-571-89713674; Email: qianwb@zju.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Relapsed/refractory multiple myeloma.
2. Confirmed by immunohistochemistry (IHC) or flow cytometry of bone marrow samples: plasma cell membrane expression of BCMA is positive (≥30%); no requirement for CD19 positivity rate. All sites must centrally submit bone marrow or plasmacytoma biopsy specimens to the lead site's pathology department or bone marrow/liquid specimens to KingMed Diagnostics (third-party laboratory) for BCMA expression verification.

3. Relapsed/refractory patients must meet the following criteria:

   No response or disease progression after 3 cycles of bortezomib (proteasome inhibitor) or lenalidomide therapy No response or disease progression after 3 cycles of prior treatment regimen Interval between last treatment and disease progression >30 days No current indication for hematopoietic stem cell transplantation (HSCT), or patient refusal of HSCT

   Definition of disease progression follows the 2021 International Myeloma Working Group (IMWG) criteria, meeting at least one of the following:

   Serum M protein ≥ 5 g/L Urine M protein ≥ 200 mg/24 h If serum free light chain (FLC) ratio is abnormal, patient FLC level ≥ 100 mg/L Biopsy-confirmed evaluable plasmacytoma Increased myeloplasmacytic percentage ≥25% (absolute increase ≥10%) Myeloplasm cells constitute ≥30% of total bone marrow cells

4. Expected survival >12 weeks;

5. Disease status is evaluable and meets at least one of the following:

   Serum M-protein ≥10 g/L, 24-hour urine M-protein ≥ 200 mg, Serum FLC ≥ 50 mg/L, Plasmacytoma evaluable by imaging or laboratory testing, Bone marrow plasma cell percentage ≥ 30%

6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
7. Sufficient venous access for apheresis or venipuncture, with no other contraindications to blood cell separation;
8. white blood cell (WBC) ≥ 1.5 × 10⁹/L; platelet (PLT) ≥ 45 × 10⁹/L.
9. Serum creatinine ≤ 1.5 times the upper limit of normal (ULN).
10. Alanine Aminotransferase (ALT) ≤ 2.5 ULN, Aspartate Aminotransferase (AST) ≤ 2.5 ULN.

All laboratory values within the above ranges must be achieved without ongoing supportive therapy.

Exclusion Criteria:

1. Received systemic therapy such as cyclophosphamide and fludarabine for lymphoma clearance within 2 weeks prior to enrollment or single-cell collection; prior CD19/BCMA CAR-T therapy; or cell or bispecific antibody therapy within 8 weeks prior to treatment.
2. Received bendamustine-containing regimens within 6 months prior to treatment.
3. Hepatitis C virus (HCV) or Human Immunodeficiency Virus (HIV) positive status; any uncontrolled active infection, including active tuberculosis or Hepatitis B virus (HBV) DNA levels ≥1×10³ copies/mL.
4. Active infection within 72 hours prior to treatment initiation; subjects on ongoing prophylactic antibiotics, antifungals, or antivirals are not excluded provided there is no evidence of active infection and the antibiotics are not on the prohibited drug list.
5. Current systemic use of cyclosporine or steroids such as dexamethasone; recent or current use of inhaled steroids is not exclusionary.
6. Renal impairment with serum creatinine >1.5 times the upper limit of normal (ULN).
7. Hepatic impairment with AST and/or ALT >2.5 times ULN and direct bilirubin >1.5 times ULN.
8. Hyponatremia, serum sodium < 125 mmol/L.
9. Baseline serum potassium < 3.5 mmol/L (exclusion not applied if potassium supplementation prior to study enrollment restores levels above this threshold).
10. Pregnant or lactating women.
11. Other serious conditions that may preclude participation in this trial (e.g., central nervous system disorders, severe heart failure, myocardial infarction within the past 6 months, unstable arrhythmia or unstable angina, gastric ulcer, active autoimmune disease, etc.).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Dual CD19/BCMA CAR-T treatment; R/R multiple myeloma patients will be treated with novel dual CD19/BCMA CAR-T	Other: Dual CD19/BCMA CAR-T; Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The incidence of adverse events	The incidence of adverse events and abnormal laboratory findings that are "possibly" or "definitely" related to the study treatment, occurring at any time from the start of monitoring until Week 24, including dose-limiting toxicity (DLT).	up to 24 weeks
Primary implant endpoint	The survival time of CAR-T cells in vivo is defined as the "engraftment endpoint." PCR detection of CAR-T cell DNA sequences begins 24 hours post-infusion at scheduled follow-up time points and continues until any two consecutive tests yield negative results, at which point the "engraftment endpoint" is recorded.	up to 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival	Overall survival	up to 2 years
complete response (CR), very good partial response (VGPR), and partial response (PR)	According to the International Myeloma Working Group (IMWG) unified response criteria for multiple myeloma	up to 2 years
Progression-free survival	Progression-free survival	up to 2 years
Detection and quantification of CD19/BCMA CAR-T cells	Detection and quantification of CD19/BCMA CAR-T cells in blood, bone marrow, and/or tumor tissue	up to 2 years
Detection and quantification of circulating soluble BCMA	Detection and quantification of circulating soluble BCMA	up to 2 years
BCMA expression	Evaluate BCMA expression in plasma cells and tumor cells	Throughout the entire follow-up period，up to 2 years
minimal residual disease (MRD)	Evaluate the minimal residual disease (MRD) required for subjects to achieve a complete response.	up to 2 years

Collaborators and Investigators

• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Collaborators: Tongji Hospital; Jinhua Municipal Central Hospital; Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
• Investigators: Principal Investigator: Wenbin Qian, Dr., Second Affiliated Hospital, School of Medicine, Zhejiang University

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2025
• Primary Completion (Estimated): October 31, 2027
• Study Completion (Estimated): October 31, 2030

Study Registration Dates

• First Submitted: December 31, 2025
• First Submitted That Met QC Criteria: January 13, 2026
• First Posted (Actual): January 22, 2026

Study Record Updates

• Last Update Posted (Actual): January 22, 2026
• Last Update Submitted That Met QC Criteria: January 13, 2026
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Keywords: CAR-T therapy
• Other Study ID Numbers: 2025-0650

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No